News | August 04, 2022
Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr
Lupin is the 6th largest company in the Indian Pharmaceutical Market
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The company has reported total income of Rs. 21.73 crores during the period ended June 30, 2022.
The company has reported total income of Rs. 1463.03 crores during the period ended June 30, 2022.
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
The company has reported total income of Rs. 128.79 crores during the period ended June 30, 2022.
he company has reported total income of Rs. 5478.62 crores during the period ended June 30, 2022.
Driven by a strong commitment to better serve its global customers in medical and consumer products, this investment represents the largest capacity expansion in Cariflex’s existing accomplishments
Biocon has reported total income of Rs. 2217.4 crores during the period ended June 30, 2022.
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
Subscribe To Our Newsletter & Stay Updated
